Amgen shares dip amid rising selling pressure

Traders Union
All News
Financial News
Amgen slides 2.24% today after earnings

Highlights

Amgen announced Q1 2026 results and a $125 million commitment to expand small-molecule research capabilities.
Institutional investors adjusted positions and the company is working with the FDA on new small cell lung cancer trials.
Technical signals are mixed with the stock trading under short- and medium-term pressure, expected to fluctuate within a $325.01–$332.21 range.

Investor rotation and R&D push follow earnings-driven sentiment shift

Amgen reported its Q1 2026 earnings, which was followed by a $125 million investment in small-molecule research facilities. Several large institutional investors adjusted their positions in Amgen during the most recent quarter. The company also highlighted ongoing collaboration with the FDA on clinical trials for small cell lung cancer, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees mounting technical and sentiment risks for Amgen at current levels. He points out sustained selling pressure below key short-term moving averages. Institutional repositioning and lingering FDA trial uncertainties also weigh on near-term confidence. Weak and mixed momentum indicators reinforce a cautious tone. "Breaking below $328.23 would likely invite more downside, so traders should maintain tight risk controls here," Kharitonov warns.

Viktoras Karapetjanc, expert at Traders Union, notes Amgen’s fundamental strength and continued commitment to innovation. He points to the $125 million investment in R&D and ongoing FDA collaboration as key catalysts. Large institutional adjustments signal dynamic capital flows, suggesting underlying investor interest. "Given the robust pipeline and recent strategic moves, the bullish structure remains intact, and I expect further growth once momentum shifts," Karapetjanc states.

Parshwa Turakhiya, analyst, observes mixed technical sentiment with buyers and sellers locked in a short-term tug-of-war. He highlights the divergence between momentum signals and oscillators, which may offer nimble traders range-based opportunities. Volatility inside the $325.01 to $332.21 band looks actionable. "Until we get a clear breakout above $335.61 or a drop below $328.23, playing the range could reward patient setups," Turakhiya advises.

Lack of momentum clarity as key oscillators diverge near support

Momentum signals are mixed for AMGN. The MACD on the daily chart gives a strong sell reading, and the Average Directional Index (ADX) indicates a weak and directionless trend. The RSI is near neutral at 49.80, with Stochastic RSI and Bull/Bear Power (BBP) pointing to overbought conditions, suggesting that buyers were in control previously; BBP also confirms recent buyer dominance. The Commodity Channel Index (CCI) offers a mild buy signal, while the Awesome Oscillator (AO) remains neutral. The nearest support is at $328.23, with dynamic resistance at the Ichimoku Kijun level of $335.61. The stock traded close to the top of today’s range after a downside opening gap of approximately $8.11, and intraday volatility is at 0.88%. Oscillators are diverging from momentum, highlighting a lack of clear intraday conviction amid prevailing downward pressure.

Earlier, analysts noted that Amgen was consolidating within a stable long-term trend despite near-term resistance and technical uncertainty. With momentum signals still mixed and price action hovering near a critical support level, traders should closely monitor whether AMGN can reclaim resistance at $335.61 to unlock renewed upside potential in the coming sessions.

Source of Data: AMGN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.